Nanobiotix/$NBTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nanobiotix
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Ticker
$NBTX
Sector
Primary listing
Employees
103
Headquarters
Website
Nanobiotix Metrics
BasicAdvanced
$976M
-
-$1.26
1.64
-
Price and volume
Market cap
$976M
Beta
1.64
52-week high
$30.35
52-week low
$2.76
Average daily volume
134K
Financial strength
Current ratio
0.633
Quick ratio
0.582
Long term debt to equity
-67.445
Total debt to equity
-74.313
Interest coverage (TTM)
-5.19%
Profitability
EBITDA (TTM)
-50.577
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-508.35%
Operating margin (TTM)
-432.39%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$115,350
Management effectiveness
Return on assets (TTM)
-41.64%
Return on equity (TTM)
113.84%
Valuation
Price to revenue (TTM)
79.58
Price to book
-12.26
Price to tangible book (TTM)
-12.26
Price to free cash flow (TTM)
-25.551
Free cash flow yield (TTM)
-3.91%
Free cash flow per share (TTM)
-0.77
Growth
Revenue change (TTM)
-75.93%
Earnings per share change (TTM)
39.60%
3-year revenue growth (CAGR)
56.37%
10-year revenue growth (CAGR)
11.46%
3-year earnings per share growth (CAGR)
-4.05%
10-year earnings per share growth (CAGR)
1.76%
What the Analysts think about Nanobiotix
Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Bulls say / Bears say
The March 2025 amendment to its global licensing agreement with Janssen shifts nearly all remaining Phase 3 NANORAY-312 trial costs to J&J, significantly reducing Nanobiotix’s operating cash burn and extending its cash runway to mid-2026 (GlobeNewswire).
In H1 2025, Nanobiotix achieved a 186% increase in revenue to €26.6 million, a narrower net loss of €5.4 million, and reduced R&D expenses, highlighting improved operational leverage after the amendment (StockTitan).
The first patient has been dosed in the Phase 2 CONVERGE trial for Stage 3 NSCLC, showing pipeline diversification beyond head and neck cancer and building momentum for JNJ-1900 (NBTXR3) (GlobeNewswire).
As of June 30, 2025, Nanobiotix held €28.8 million in cash, providing funding only into mid-2026. The company disclosed material uncertainty about its ability to continue as a going concern unless it obtains €8–10 million in additional funding within 12 months (SEC).
H1 2025 revenue was elevated by a non-cash €21.2 million adjustment from the J&J contract amendment. Underlying recurring revenue levels remain low until regulatory approvals and commercial sales are realized (StockTitan).
Key future cash flows depend on milestone payments under the amended J&J agreement. While this still provides a ~$2.6 billion potential upside, actual payouts are conditional on regulatory approvals and trial outcomes that could face notable delays or failures (TipRanks).
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Nanobiotix Financial Performance
Revenues and expenses
Nanobiotix Earnings Performance
Company profitability
Nanobiotix News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nanobiotix stock?
Nanobiotix (NBTX) has a market cap of $976M as of November 08, 2025.
What is the P/E ratio for Nanobiotix stock?
The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of November 08, 2025.
Does Nanobiotix stock pay dividends?
No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Nanobiotix dividend payment date?
Nanobiotix (NBTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix?
Nanobiotix (NBTX) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.